In a post hoc subgroup analysis of the longest TD study to date (open-label extension, non-blinded)1,2

Rapid TD symptom control as early as 2 weeks* with sustained results observed through ~3 years in patients with mood disorders2,3

Mood Disorder Subgroup: AIMS Score Reduction in RIM-TD Study2,3

7.1-POINT REDUCTION

vs baseline

*Symptom control defined as change in AIMS total score as early as Week 2 in placebo-controlled studies.3

The mood disorder subgroup included patients with bipolar disorder and depression.2

Mean total dose.3

Growing percentage of patients with mood disorders achieved ≥50% AIMS score improvement over time2

Patients With ≥50% Reduction in AIMS Total Score2

AUSTEDO

Week 54

56%

N=105

Week 106

61%

N=83

Week 145

67%

N=72

Percentage
of patients

0 10 20 30 40 50 60 70 80 90 100

In a post hoc subgroup analysis of the longest TD study to date (open-label extension, non-blinded)1,2

Rapid TD symptom control as early as 2 weeks§ with sustained results observed through ~3 years in patients with schizophrenia2,3

Schizophrenia Subgroup||: AIMS Score Reduction in RIM-TD Study2,3

§Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.3

||Schizophrenia subgroup included patients with schizophrenia and schizoaffective disorder.2

Mean total dose.3

Growing percentage of patients with schizophrenia achieved ≥50% AIMS score improvement over time2

Patients With ≥50% Reduction in AIMS Total Score2

AUSTEDO

Week 54

44%

N=142

Week 106

50%

N=107

Week 145

67%

N=86

Percentage
of patients

0 10 20 30 40 50 60 70 80 90 100

AIMS, Abnormal Involuntary Movement Scale; TD, tardive dyskinesia.


REFERENCES: 1. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 2. Hauser RA, Barkay H, Fernandez HH, et al. Effects of long-term deutetrabenazine treatment in patients with tardive dyskinesia and underlying psychiatric or mood disorders. Presented at: Psych Congress; October 29-November 1, 2021; San Antonio, TX. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.